Background/Aims: Recent studies have suggested that several lncRNAs contribute to the angiogenic function of endothelial cells. Herein, we set out to reveal whether lncRNA UCA1 has functions in endothelial angiogenesis. Methods: The expression levels of lncRNA UCA1, miR-195 and CCND1 in human microvascular endothelial HMEC-1 cells were altered by transfection. Subsequently, cell viability, migration, tube formation and apoptosis of HMEC-1 cells were respectively assessed. The cross-talk between lncRNA UCA1, miR-195, CCND1, and MEK/ERK and mTOR signaling pathways were investigated by performing qRT-PCR and Western blotting. Results: Silence of lncRNA UCA1 repressed HMEC-1 cells viability, migration, tube formation, and induced apoptosis. Meanwhile, silence of lncRNA UCA1 significantly up-regulated miR-195 expression. These alterations induced by lncRNA UCA1 were further enhanced by miR-195 overexpression, while were attenuated by miR-195 suppression. Moreover, silence of lncRNA UCA1 deactivated MEK/ERK and mTOR signaling pathways via a miR-195-dependent regulation. And the deactivation of MEK/ERK and mTOR signaling pathways led to a down-regulation of CCND1. Conclusion: This study demonstrates that silence of lncRNA UCA1 largely represses microvascular endothelial cells growth and tube formation. Silence of lncRNA UCA1 exerts its function possibly via up-regulation of miR-195, which in turn inactivates MEK/ERK and mTOR signaling pathways, and ultimately represses CCND1 expression.
Introduction
Atherosclerosis is a consequence of coronary artery disease, stroke, and peripheral artery disease. If not treated promptly, atherosclerosis can cause the ischemia and necrosis of limbs, and eventually result in amputation. Current therapies prevent vein graft atherosclerosis and are essentially limited to lipid-lowering drugs, typically statins [1] , fibrates [2] , niacin [3] , and ezetimibe [4] . Lipid-lowering drugs decrease low-density lipoprotein cholesterol (LDL-C) level and reduce the risk of atherosclerotic cardiovascular diseases. However, many high-risk people have levels of LDL-C that remain unacceptably high despite being treated with maximally tolerated doses of lipid-lowering drugs [5] . Thus, a better understanding of atherosclerosis is still required to improve the therapeutic strategy of atherosclerosis.
Non-coding RNAs (ncRNAs) cover more than 98% of the human genome [6] . Among yet, microRNAs (miRNAs) have been extensively studied, while little is known about the role of long ncRNAs (lncRNAs). Recent studies have partially revealed the regulatory functions of lncRNAs in complex human diseases, such as a variety of cancers [7] , neurological disorder [8] and atherosclerosis [9] . Further investigations indicate that lncRNAs may regulate the biological processes of atherosclerosis-related endothelial cells, especially angiogenesis. For the selected examples, it has been reported that silence of lncRNA MEG3 rescued age-induced impairment of angiogenesis [10] . LncRNA SENCR has been described to be significantly upregulated in endothelial derivatives of human embryonic stem cells, and it controlled the sprouting and migratory capacity of endothelial cells [11] .
Urothelial carcinoma associated 1 (UCA1), a lncRNA initially discovered in bladder cancer [12] , which has been reported to be an oncogenic gene in many cancers, including bladder cancer [13] , gastric cancer [14] , oral squamous cell carcinoma [15] , and prostate cancer [16] . Recent literatures have mainly focused on the expression pattern and the function of lncRNA UCA1 in various cancers, and the pivotally regulatory role of lncRNA UCA1 in cancer cells proliferation, invasion, migration, and apoptosis has been widely reported [13, 14, 17] . Besides, although the underling mechanisms of which lncRNA UCA1 functioned to malignant growth and metastasis are still a mystery, bioinformatics analyses have suggested that it might be by sponging miRNAs, and thereby quarantining the target gene of miRNAs from degradation [15] .
To date, little is known regarding the exact role of lncRNA UCA1 in atherosclerosis. This study concerned about this issue by investigating the functional effect of lncRNA UCA1 silence on human microvascular endothelial HMEC-1 cells growth and tube formation. Additionally, the cross-talk between lncRNA UCA1 and miR-195 was explored to identify whether miR-195 (a cardiovascular-associated miRNA [18, 19] ) was involved in the action of lncRNA UCA1.
Materials and Methods

Cell culture
Human microvascular endothelial HMEC-1 cells purchased from American Type Culture Collection (Cat. No: CRL-3243; ATCC, Manassas, VA, USA) were cultured in Dulbecco's Modified Eagle's Medium (Sigma-Aldrich, St. Louis, MO, USA). Heat-inactivated fetal bovine serum (Life Technologies, Cergy Pontoise, France) was supplemented into the culture medium with a final concentration of 10% (v/v). The cells were maintained at 37°C in a humidified 5% CO 2 incubator. Third to seventh passages were used for angiogenesis assay. Third to tenth passages were used for other assays.
For the inhibition of MEK and mTOR pathways, cells were respectively treated with 10 nM AZD6244 (Selleck Chemicals, Houston, TX, USA) and 20 μM Tamoxifen (Sigma-Aldrich, St. Louis, MO, USA) for 24 h. 
Transfection
For lncRNA UCA1 silencing, shRNA anti-human lncRNA UCA1 was lighted into the pGPU6/Neo plasmid (GenePharma, Shanghai, China). A non-targeting sequence was used as a blank control. For miR-195 overexpression and suppression, the specific mimic and inhibitor for human miR-195 were transfected into cell. The synthesized sequence of cel-miR-67-3p was transfected as a blank control. The full-length wild-type of CCND1 was cloned into a pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) to make a CCND1 expression vector. An empty pcDNA3.1 vector was transfected as a blank control. CCND1 shRNA plasmid (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was transfected in order to silence the expression of CCND1. A non-targeting sequence was used as a blank control. All transfection was performed by using Lipofectamine 3000 reagent (Life Technologies Corporation, Carlsbad, CA, USA). At 48 h of transfection, cells were collected and the transfection efficiency was verified by qRT-PCR or Western blot analysis.
qRT-PCR
Total RNA was extracted from cell by using TRI Reagent (Sigma-Aldrich). The purity and concentration of the extract RNA were tested by SMA 400-UV-VIS (Merinton, Shanghai, China). For the test of VEGF, VEGFR2, CD144, eNOS, lncRNA UCA1, and CCND1, the PrimerScript 1 st Strand cDNA Synthesis Kit (Invitrogen) was used for cDNA synthesis, and the SYBR ExScript RT-qPCR Kit (Takara, Dalian, China) was used for qRT-PCR. β-actin was used as an internal control in this procedure. For the test of miR-195, the Taqman MicroRNA Reverse Transcription Kit and Taqman Universal Master Mix II (both from Applied Biosystems, Foster City, CA, USA) were used for cDNA synthesis and qRT-PCR respectively. U6 acted as an internal control. Data were calculated by relative quantification (2−ΔΔCt) method.
Cell viability assessment
The viability of transfected cells were detected by using Cell Counting Kit-8 (CCK-8, Dojindo Molecular Technologies, Kyushu, Japan). The transfected cells were planted into 96-well plants with a density of 5000 cells/well. After 48 h of incubation, the culture medium was removed and 10 μl CCK8 was added into each well. Following 4 h of incubation at 37°C, the absorbance of each well was measured by a Bio-Rad Microplate Reader 550 (Bio-Rad, Hercules, CA, USA) at 450 nm.
Quantitation of apoptosis
The apoptosis of the transfected cells was tested by using an Annexin V-FITC/PI Apoptosis Detection Kit (Qcbio Science & Technologies Co., Ltd, Shanghai, China). Cells (1 × 10 5 ) were resuspended in 100 μl Binding Buffer containing 5 μl Annexin V-FITC and 10 μl PI Staining Solution. The samples were incubated at room temperature for 15 min in the dark, after which 400 μl Binding Buffer was added. Flow cytometry analysis was done by using a FACS can (FACS Calibur, Beckman Coulter, Fullerton, CA, USA). The percentage of apoptotic cells (Annexin V-FITC positive and PI negative) was calculated by FlowJo software version 7.6.4 (Tree Star, San Carlos, California, USA).
Transwell assay
Transwell assay was performed to detect cell migration by using a modified Boyden chamber (CostarCorning, New York, USA). The transfected cells (1 × 10 5 ) were placed in the upper chamber with serum-free medium. The lower chamber was filled with 200 μl complete medium. The cells were incubated at 37°C for 24 h, after which the non-traversed cells in the upper side were removed by cotton swabs, and the cells in the lower side were stained with crystal violet (Beyotime, Nantong, China) for 30 min. The stained cells were then counted under an optical microscope (BX51 system, Olympus, Tokyo, Japan).
In vitro angiogenesis assay
For angiogenesis assay, 6-well plates were pre-coated with matrigel (BD Biosciences, San Jose, CA, USA). Then, 1 × 10 5 HMEC-1 cells were seeded into each well. After 24 h of culturing at 37°C, the formation of capillary-like structures was photographed and the number of capillary-like structures was counted. The tube length was analyzed by the AxioVision Rel software version 4.8 (Carl Zeiss AG, Jena, Germany) [20] . Western blot analysis Cellular protein was isolated by using RIPA lysis buffer (Beyotime, Shanghai, China). The purity and concentration of the extract protein were verified by the BCA™ Protein Assay Kit (Pierce, Appleton, WI, USA). Protein (0.1 mg) from each sample was resolved over SDS-PAGE and transferred onto a polyvinylidene fluoride membrane. The membranes were blocked in 5% non-fat milk for 1 h at room temperature, and then incubated at 4°C overnight with primary antibodies: anti-VEGF (5365-100, BioVision, Milpitas, CA, USA), anti-VEGFR2 (OAEC00429, Aviva Systems Biology, San Diego, CA, USA), anti-CD144 (sc-52751), antiBcl-2 (sc-509), anti-Bax (sc-6236), anti-caspase-3 (sc-271028), anti-caspase-9 (sc-133109), anti-CCND1 (sc-450), anti-β-actin (sc-130300, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-eNOS (ab76198),
The membranes were then incubated with the secondary antibodies for 1 h at room temperature, and the signals were visualized by enhanced chemiluminescence method. The intensity of the bands was quantified using Image Lab™ Software version 5.0 (Bio-Rad, Laboratories, Hercules, CA, USA).
Statistics
Excepted for Western blot analysis, data are given as means ± SD. Statistical analysis was performed by using the SPSS version 19.0 program (SPSS Inc., Chicago, IL, USA). Statistical differences between two or more groups were analyzed by using a one-way analysis of variance (ANOVA) with Duncan post-hoc. Before ANOVA, all data were tested for normal distribution and similarity of variance. P values of <0.05 was considered as significant.
Results
Tube formation of HMEC-1 cells
HMEC-1 cells were grown in matrigel-coated plates for 24h, and the formation of capillary-like tubes was monitored. As shown in Fig. 1A-1B , the length and rate of capillarylike tubes were increased significantly with the prolongation of time (P < 0.05). In addition, the mRNA and protein levels of VEGF, VEGFR2, CD144 and eNOS were all significantly increased in a time-dependent manner (Fig. 1C-1D , P < 0.05). Compared to other time points, 24 h of culturing achieved a greatest tube formation and highest protein levels of angiogenesis-related factors. Thus, 24 h was selected as a culturing condition for use in the following experiments.
LncRNA UCA1 silence repressed HMEC-1 cells growth and tube formation capacity
To test the potential role of lncRNA UCA1 in the angiogenesis of endothelial cells, the expression of lncRNA UCA1 in HMEC-1 cells was silenced by shRNA transfection (P < 0.05, Fig. 2A) . Silence of lncRNA UCA1 by shRNA-based knockdown significantly decreased cell viability, migration, and tube formation (P < 0.05, Fig. 2B-2E ), while significantly increased apoptotic cell rate (P < 0.05, Fig. 2F ). Besides, silence of lncRNA UCA1 down-regulated the protein expression of Bcl-2, up-regulated the protein expression of Bax, and remarkably cleaved caspase-3 and caspase-9 (Fig. 2G) .
LncRNA UCA1 silence up-regulated the expression of miR-195
A previous study has revealed that lncRNA UCA1 was a molecular sponge for miR-195 in bladder cancer cells [13] . Herein, we studied whether lncRNA UCA1 functioned to HMEC-1 cells also in a miR-195-dependent regulation. By performing qRT-PCR we found that the RNA level expression of miR-195 was significantly increased by genetic deletion of lncRNA UCA1 (P < 0.05, Fig. 3 
LncRNA UCA1 silence repressed HMEC-1 cells growth and tube formation via up-regulation of miR-195
To establish a link between miR-195 and endothelial angiogenic capacity, the mimic and inhibitor specific for miR-195 were transfected into HMEC-1 cells. As shown in Fig. 4A , the expression of miR-195 was significantly increased by mimic transfection, while was significantly reduced by inhibitor transfection (P < 0.05). The decreases in viability, migration, and tube formation induced by lncRNA UCA1 silence were significantly accelerated by miR-195 mimic, while were significantly attenuated by miR-195 inhibitor (P < 0.05, Fig. 4B-4E) . Also, lncRNA UCA1 silence induced apoptosis was accelerated by miR-195 mimic, and was attenuated by miR-195 inhibitor, as evidenced by the changes in apoptotic cell rate and protein levels of apoptosis-related factors (P < 0.05, Fig. 4F-4G ).
LncRNA UCA1 silence deactivated MEK/ERK and mTOR signaling pathways via upregulation of miR-195
To get insights into the molecular mechanism by which lncRNA UCA1 controls endothelial cells function, we tested the activation of MEK/ERK and mTOR signaling pathways. Data in Fig. 5A and 5B demonstrated that, phosphorylation forms of MEK, ERK, mTOR and S6K were all remarkably down-regulated, while the total levels of these proteins were unchanged in response to lncRNA UCA1 silence. As compared to the sh-NC+NC group, the ratio of phospho/total (p/t)-MEK, p/t-ERK, p/t-mTOR and p/t-S6K were all significantly decreased in sh-UCA1+NC group (P < 0.05), indicating lncRNA UCA1 silence repressed the activation of MEK/ERK and mTOR signaling. Moreover, we found that the deactivation induced by lncRNA UCA1 silence was further enhanced by miR-195 mimic, while was recovered by miR-195 inhibitor (P < 0.05). 
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LncRNA UCA1 silence decreased the expression of CCND1
The deactivation of MEK/ERK and mTOR signaling induced by lncRNA UCA1 silence was further studied by using two inhibitors of MEK and mTOR, i.e., AZD6244 and Tamoxifen. Results showed that the elevated levels of p-MEK and p-ERK were both suppressed by AZD6244 treatment (Fig. 6A) . Also, the elevated levels of p-mTOR and p-S6K were both suppressed by Tamoxifen treatment (Fig. 6B) . Additionally, the protein expression of CCND1 was decreased by sh-UCA1, and was increased by miR-195 inhibitor. More interestingly, AZD6244 and Tamoxifen flattened the increase of CCND1 levels induced by miR-195 inhibitor.
CCND1 promoted HMEC-1 cells growth and tube formation
To address the question whether CCND1 contributed to endothelial cells angiogenesis, the expression level of CCND1 was overexpressed or suppressed by transfection. The mRNA and protein levels of CCND1 were significantly increased by pc-CCND1 transfection, while were decreased by sh-CCND1 transfection (P < 0.05, Fig. 7A ). As expected, cell viability, migration, and tube formation were significantly increased by pc-CCND1, while were significantly reduced by sh-CCND1 (P < 0.05, Fig. 7B-7E ). Apoptosis was not reduced by pc-CCND1, perhaps because the apoptosis in control group was already pretty low; but apoptosis was significantly induced by sh-CCND1 (P < 0.05, Fig. 7F-7G ).
Discussion
Plaque angiogenesis is one of the important contributors to unstable lesions [21] . It can cause occlusive thrombosis and finally cause a variety of acute cardiovascular events [22] . In angiogenesis-driving processes, endothelial cells proliferation, migration and invasion are involved in angiogenic sprouting [23] . Besides, endothelial cells proliferation and tube formation are driven by VEGF and its receptors (VEGFR1 and VEGFR2) [24] . In addition to VEGF, CD144 and eNOS are two other important players in angiogenesis. eNOS mobilizes endothelial progenitor cells from bone marrow to peripheral blood, and causes ischemiainduced vascularization [25] . The dynamics of CD144 is required for angiogenic endothelial cells migration and positional changes [26] . In this study, we investigated the role and mechanism of lncRNA UCA1 in human microvascular endothelial HMEC-1 cells growth and tube formation. We demonstrated that silence of lncRNA UCA1 repressed HMEC-1 cells viability, migration, tube formation, and accelerated a mitochondria initiated apoptosis. Meanwhile, miR-195 was highly expressed by lncRNA UCA1 silence. Rescue experiments identified that lncRNA UCA1 conferred its function might be partially via regulating miR-195 expression. We further found that miR-195 may inactivate MEK/ERK and mTOR signaling pathways, which in turn repress CCND1 expression.
The functional role of lncRNA UCA1 in endothelial cells angiogenesis is largely unknown to date. However, a previous study has reported that lncRNA UCA1 was up-regulated in lymphatic endothelial cells of type 2 diabetic patients, demonstrating an important role of lncRNA UCA1 in lymphatic endothelial cells [27] . This was confirmed by a study of Sethuraman et al., in which knockdown of lncRNA UCA1 has been pointed out to induce a reduction of proliferation and migration in endothelial cells [28] . In the current study, lncRNA UCA1 knockdown significantly repressed HMEC-1 cells viability, migration and tube formation, and significantly induced apoptosis. This finding suggested that lncRNA UCA1 might be one of the pro-angiogenic factors in atherosclerosis, and provided in vitro evidences that lncRNA-related strategies will be beneficial in patients with atherosclerosis.
It has been widely reported that miR-195 exerted inhibitory effects on angiogenesis in a wide range of cancers, such as hepatocellular carcinoma [29] , prostate cancer [30] and breast cancer [31] . miR-195 inhibited the expression of pro-angiogenic factor VEGF and the prometastatic factors VAV2 and CDC42 [29] . More interestingly, miR-195 was highly expressed in a specific endothelium which is strongly positive for CD31 and endomucin (CD31 The activation of MEK/ERK signaling pathway is pivotal in modulating a number of cellular processes, including proliferation and angiogenesis [34] . MEK activation is the upstream signaling event that leads to the activation of ERK. During atherosclerosis, ERK modulates macrophage cholesterol homeostasis and key genes implicated in atherosclerosis [35] . Besides, multiple researchers have suggested that mTOR may offer new avenues in the regression of atherosclerotic plaques [36, 37] . mTOR contributes in proliferation, lipogenesis, and energy metabolism possibly by targeting S6K and cyclin-dependent kinases (CDKs) [38] . Previous studies have evidenced that lncRNA UCA1 promoted malignant transformation and cancer progression through activation of mTOR pathway [14, 39] . However, the regulation between lncRNA UCA1 and MEK/ERK pathway has not been revealed yet. In the current study, we demonstrated that lncRNA UCA1 silence up-regulated miR-195 to deactivate MEK/ERK and mTOR signaling pathways. Additionally, we demonstrated that blockage of MEK/ERK and mTOR signaling pathways by using their corresponding inhibitors (AZD6244 and Tamoxifen) led to the down-regulation of CCND1, indicating CCND1 might be one of the executors in the revealed regulation system. Furthermore, this hypothesis was confirmed in the functional experiments, from which the pro-growth, pro-migratory, and pro-tube formation effects of CCND1 were observed.
This study highlighted the potential anti-angiogenic effect of lncRNA UCA1 silence on HMEC-1 cell line under normal conditions. Since other types of cells, such as macrophage, foam cells, monocytes and smooth muscle cells are also implicated in the pathogenesis of atherosclerosis, the role of lncRNA UCA1 in these cells are required to be further studied. Additionally, the regulatory impacts of lncRNA UCA1 on the release of inflammatory cytokines and LDL cholesterol are needed to be studied which will largely improve our understanding of lncRNA UCA1 in atherosclerosis.
Conclusion
In conclusion, our study demonstrates that silence of lncRNA UCA1 represses microvascular endothelial cells growth and tube formation capacity. Silence of lncRNA UCA1 exerts its function possibly via up-regulation of miR-195, which in turn inactivates MEK/ ERK and mTOR signaling pathways, and ultimately represses CCND1 expression (Fig. 8) . This finding provided the first evidence that lncRNA UCA1 played significant roles in endothelial dysfunction. 
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